体外診断（IVD）用原材料市場規模、シェア、動向、2031年までの世界予測

体外診断（IVD）用原材料市場は、2026年の215億米ドルから2031年には311億米ドルへと、年平均成長率（CAGR）7.7%に達するとMarketsandMarketsでは予測しています。この成長の背景には、慢性疾患や感染症の有病率の増加、疾患の早期かつ正確な診断に対する需要の高まり、そして高度な診断技術の普及拡大があります。PCR、NGS、FISH、LAMPといった分子診断技術の利用拡大に伴い、高品質なオリゴヌクレオチド、核酸、酵素、その他の特殊な原材料に対する需要が増大しています。同時に、ポイント・オブ・ケア検査（POCT）の急速な普及により、迅速診断アッセイに使用される抗体、抗原、メンブレン、標識、検出用素材へのニーズも高まっています。さらに、組換え技術、タンパク質工学、アッセイ開発の進歩が、診断検査の性能、感度、信頼性を向上させています。こうした技術革新によって、診断薬メーカーはより正確かつ効率的な検査ソリューションを開発できるようになり、それが世界的なIVD用原材料市場の成長を後押ししています。

調査対象範囲：

本調査レポートでは、体外診断（IVD）用原材料市場を以下の区分で分析しています：製品タイプ（抗体、抗原・タンパク質、酵素・基質、オリゴヌクレオチド・核酸、ビーズ・粒子、メンブレン、標識・検出用材料、緩衝液・希釈液、その他）、技術（免疫測定、分子診断、臨床化学、血液検査、微生物・培養検査、凝固検査、ポイント・オブ・ケア検査、フローサイトメトリー、その他）、用途（感染症検査、腫瘍・がんマーカー、心疾患マーカー、糖尿病・代謝疾患、自己免疫疾患、血液スクリーニング、女性の健康・生殖医療、遺伝性疾患・希少疾患検査、その他）、供給形態（自社製造、第三者供給）、由来・起源（生物学的・天然由来、組換え・合成、その他）、エンドユーザー（IVDメーカー、受託研究機関[CRO]、学術・研究機関、製薬・バイオテクノロジー企業、その他）、および地域（北米、欧州、アジア太平洋、中南米、中東・アフリカ）。本レポートは、IVD原材料市場の成長に影響を与える主要因（促進要因、阻害要因、機会、課題）に関する詳細情報も網羅しています。主要な業界プレーヤーについては詳細な分析を行い、事業概要、製品ポートフォリオ、買収・提携・共同開発・生産能力拡大・新製品投入などの主要戦略、およびIVD原材料市場に関連する最近の動向について知見を提供します。また、IVD原材料のエコシステムにおける新興企業や市場参加者の競合分析も含まれています。

本レポートを購入する理由：

本レポートは、IVD原材料市場全体および各セグメントの推定収益データを提供することで、市場のリーダー企業や新規参入企業を支援します。ステークホルダーは、競争環境を把握し、より深い洞察を得ることで、自社の事業の立ち位置を明確にし、適切な市場参入戦略を策定することが可能になります。さらに、市場の動向を理解し、主要な促進要因、阻害要因、機会、課題に関する情報を得るのにも役立ちます。

本レポートでは、以下の点に関する知見を提供します：

IVD（体外診断）用原材料市場の成長に影響を与える要因の分析：主要な促進要因（高齢者人口の増加とそれに伴う慢性疾患の増加、新興国における早期診断への意識の高まり、迅速なポイント・オブ・ケア（POC）技術の登場と自動分析装置の普及、個別化医療への関心の高まり）、阻害要因（不利な償還制度、厳しい規制要件）、機会（疾患特異的バイオマーカーや検査法の導入、コンパニオン診断の重要性増大、発展途上国における成長機会、免疫測定技術の向上、デジタル化の進展）、および課題（ロット間の均一性や原材料品質の維持、重要な生物学的・合成試薬の供給に影響を及ぼすサプライチェーンの混乱）

• 製品開発・イノベーション：IVD用原材料市場における次世代技術、研究開発活動、新製品投入に関する詳細な情報
• 市場開拓：有望な市場に関する包括的な情報（本レポートでは、様々な地域におけるIVD用原材料市場を分析しています）
• 市場の多角化：IVD用原材料市場における新製品、未開拓地域、最近の動向、投資に関する詳細な情報
• 競合分析：Merck KGaA（ドイツ）、Thermo Fisher Scientific Inc.（米国）、Medix Biochemica（フィンランド）、Bio-Techne Corporation（米国）、Fapon Biotech Inc.（中国）などの主要企業における市場シェア、成長戦略、製品ポートフォリオの詳細な評価

Report Description

The IVD raw material market is projected to grow from USD 21.5 billion in 2026 to USD 31.1 billion by 2031, growing at a CAGR of 7.7%. The increasing prevalence of chronic and infectious diseases, the rising demand for early and accurate disease diagnosis, and the expanding adoption of advanced diagnostic technologies. The growing use of molecular diagnostic techniques such as PCR, NGS, FISH, and LAMP is increasing demand for high-quality oligonucleotides, nucleic acids, enzymes, and other specialized raw materials. At the same time, the rapid expansion of point-of-care testing is driving the need for antibodies, antigens, membranes, labels, and detection materials used in rapid diagnostic assays. Furthermore, advancements in recombinant technologies, protein engineering, and assay development are improving the performance, sensitivity, and reliability of diagnostic tests. These innovations are enabling diagnostic manufacturers to develop more accurate and efficient testing solutions, thereby supporting the growth of the global IVD raw material market.

“The infectious disease testing segment is expected to account for the largest share of the IVD raw material market, by application, during the forecast period.”

Based on application, the IVD raw material market is segmented into infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women’s health & fertility, genetic & rare disease testing, and others. The infectious disease testing segment accounts for the largest market share due to the high global burden of infectious diseases and the increasing demand for rapid, accurate, and large-scale diagnostic testing. Diagnostic manufacturers extensively use raw materials such as antibodies, antigens, enzymes, oligonucleotides, nucleic acids, and detection reagents to develop immunoassays, molecular diagnostic tests, and point-of-care testing solutions for detecting bacterial, viral, fungal, and parasitic infections. Additionally, growing investments in public health programs, increasing awareness of early disease diagnosis, and the continued adoption of advanced molecular diagnostic technologies are driving demand for high-quality IVD raw materials in infectious disease testing, making it the largest application segment of the market.

“The immunoassay segment has the largest market share in the IVD raw material market during the forecast period.”

The global IVD raw material market can be segmented by technology into immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others. Among these, the immunoassay segment accounted for the largest market share. Immunoassay-based diagnostics remain a fundamental component of routine disease testing due to their high sensitivity, specificity, cost-effectiveness, and broad application across infectious diseases, oncology, cardiac markers, autoimmune disorders, and hormone testing. The widespread adoption of immunoassay platforms has generated substantial demand for critical raw materials, including antibodies, antigens, proteins, enzymes, labels, and detection reagents. Furthermore, continuous advancements in assay development, increasing diagnostic testing volumes, growing demand for rapid and accurate diagnostic solutions, and the expansion of automated immunoassay analyzers are expected to support the continued adoption of immunoassay technologies, thereby driving demand for IVD raw materials worldwide.

“Asia Pacific: The fastest-growing market for IVD raw material from 2026 to 2031”

The global IVD raw material market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region’s growth is driven by the increasing prevalence of chronic and infectious diseases, expanding healthcare infrastructure, rising investments in diagnostic technologies, and growing demand for early and accurate disease diagnosis. China is strengthening its domestic diagnostic manufacturing capabilities through healthcare modernization initiatives and increased investment in biotechnology and life sciences. India is witnessing significant growth in diagnostic testing volumes, supported by the expansion of clinical laboratories and molecular diagnostic facilities, as well as the adoption of point-of-care testing. Additionally, Japan’s advanced healthcare system, aging population, and strong focus on precision medicine continue to drive demand for high-quality diagnostic assays and the raw materials required for their development. These factors are expected to support the rapid growth of the IVD raw material market across the Asia Pacific region during the forecast period.

The break-up of the profile of primary participants in the IVD raw market:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier – 30%
• By Designation: C-level Executives – 27%, Directors – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa – 4%

Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Medix Biochemica (Finland), Bio-Techne Corporation (U.S.), Fapon Biotech Inc. (China), Meridian Bioscience, Inc. (U.S.), BBI Solutions (U.K.), Toyobo Co., Ltd. (Japan), Roche CustomBiotech (Switzerland), Integrated DNA Technologies, Inc. (U.S.), Cytiva (U.S.), Sartorius AG (Germany), LGC Biosearch Technologies (U.S.), Fitzgerald Industries International (U.S.), and Bangs Laboratories, Inc. (U.S.) are some of the key players operating in the global IVD raw material market.

Research Coverage:

This research report categorizes the IVD raw material market by product type (antibodies, antigens & proteins, enzymes & substrates, oligonucleotides & nucleic acids, beads & particles, membranes, labels & detection materials, buffers & diluents, and others), by technology (immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others), by application (infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women’s health & fertility, genetic & rare disease testing, and others), by supply source (in-house manufacturing [captive] and third-party supply [merchant]), by source/origin (biological/natural source, recombinant/synthetic, and others), by end user (IVD manufacturers, contract research organizations, academic & research institutes, pharmaceutical & biotech companies, and others), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the IVD raw material market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies such as acquisitions, partnerships, collaborations, capacity expansions, and product launches, as well as recent developments associated with the IVD raw material market. Competitive analysis of emerging companies and market participants within the IVD raw materials ecosystem is also covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD raw material market and the subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid point-of-care [POC] technologies and rising adoption of automated analyzers, and growing preference for personalized medicine), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, improvements in immunoassay diagnostic technologies, and the growing digitalization trend), and challenges (maintaining batch-to-batch consistency and quality of raw materials, and supply chain disruptions affecting the availability of critical biological and synthetic reagents) influencing the growth of the IVD raw material market

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the IVD raw material market
• Market Development: Comprehensive information about lucrative markets—the report analyzes the IVD raw material market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD raw material market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product portfolios of leading players such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Medix Biochemica (Finland), Bio-Techne Corporation (U.S.), and Fapon Biotech Inc. (China), among others

Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 42
1.3.2 INCLUSIONS AND EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.3.4 CURRENCY CONSIDERED 44
1.4 STAKEHOLDERS 44
2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 47
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 48
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 IVD RAW MATERIALS MARKET OVERVIEW 50
3.2 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2026 VS. 2031 51
3.3 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2026 VS. 2031 51
3.4 IVD RAW MATERIALS MARKET, BY APPLICATION, 2026 VS. 2031 52
3.5 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2026 VS. 2031 52
3.6 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2026 VS. 2031 53
3.7 IVD RAW MATERIALS MARKET, BY END USER, 2026 VS. 2031 53
3.8 IVD RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 55
4.2.1 DRIVERS 56
4.2.1.1 Rising prevalence of chronic and infectious diseases 56
4.2.1.2 Growing adoption of personalized medicine and companion diagnostics 56
4.2.1.3 Increasing use of recombinant antibodies, proteins, and enzymes 57
4.2.1.4 Growing demand for raw materials supporting decentralized and rapid diagnostics 58

4.2.2 RESTRAINTS 58
4.2.2.1 High validation and quality-control costs 58
4.2.2.2 Long supplier qualification cycles 59
4.2.2.3 Limited availability of specialized biological raw materials 59
4.2.3 OPPORTUNITIES 60
4.2.3.1 Adoption of recombinant and animal-free raw materials 60
4.2.3.2 Localization of raw material manufacturing in emerging markets 60
4.2.3.3 Development of next-generation molecular diagnostic reagents 61
4.2.4 CHALLENGES 62
4.2.4.1 Maintaining batch-to-batch consistency 62
4.2.4.2 Building resilient supply chains for critical biological inputs 62
4.2.4.3 Meeting evolving IVDR/FDA supplier documentation requirements 63
4.3 UNMET NEEDS AND WHITE SPACES 63
4.3.1 UNMET NEEDS IN IVD RAW MATERIALS MARKET 63
4.3.2 WHITE SPACE OPPORTUNITIES 64
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 65
4.4.1 INTERCONNECTED MARKETS 65
4.4.2 CROSS-SECTOR OPPORTUNITIES 65
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 66
4.5.1 KEY MOVES AND STRATEGIC FOCUS 66
5 INDUSTRY TRENDS 68
5.1 PORTER’S FIVE FORCES ANALYSIS 68
5.1.1 THREAT OF NEW ENTRANTS 69
5.1.2 THREAT OF SUBSTITUTES 69
5.1.3 BARGAINING POWER OF SUPPLIERS 69
5.1.4 BARGAINING POWER OF BUYERS 70
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.2 MACROECONOMIC INDICATORS 70
5.2.1 INTRODUCTION 70
5.2.2 GDP TRENDS AND FORECAST 70
5.3 SUPPLY CHAIN ANALYSIS 72
5.4 VALUE CHAIN ANALYSIS 73
5.5 ECOSYSTEM ANALYSIS 75
5.6 PRICING ANALYSIS 76
5.6.1 AVERAGE SELLING PRICE, BY REGION, 2024–2026 76
5.6.2 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024–2026 77
5.7 TRADE ANALYSIS 78
5.7.1 IMPORT SCENARIO (HS CODE 300213) 78
5.7.2 EXPORT SCENARIO (HS CODE 300213) 78
5.8 KEY CONFERENCES & EVENTS, 2026–2027 79
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79
5.10 INVESTMENT & FUNDING SCENARIO 80
5.11 IMPACT OF US TARIFFS—IVD RAW MATERIALS MARKET 81
5.11.1 INTRODUCTION 81
5.11.2 KEY TARIFF RATES 81
5.11.3 PRICE IMPACT ANALYSIS 82
5.11.4 IMPACT ON REGIONS 82
5.11.4.1 North America 82
5.11.4.2 Europe 82
5.11.4.3 Asia Pacific 83
5.11.5 IMPACT ON END-USE INDUSTRIES 83
5.11.5.1 OEM IVD manufacturers 83
5.11.5.2 Biopharmaceutical companies 83
5.11.5.3 CROs and research institutions 83
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 84
6.1 KEY EMERGING TECHNOLOGIES 84
6.1.1 IMMUNOASSAY 84
6.2 COMPLEMENTARY TECHNOLOGIES 84
6.2.1 MOLECULAR DIAGNOSTICS 84
6.3 TECHNOLOGY/PRODUCT ROADMAP 85
6.4 PATENT ANALYSIS 87
6.4.1 LIST OF KEY PATENTS 88
6.5 FUTURE APPLICATIONS 88
6.6 IMPACT OF AI/GENERATIVE AI ON IVD RAW MATERIALS MARKET 89
6.6.1 INTRODUCTION 89
6.6.2 TOP USE CASES AND MARKET POTENTIAL 90
6.6.3 KEY COMPANIES IMPLEMENTING AI 90
6.6.4 FUTURE OF AI 91
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 92
7.1 REGIONAL REGULATIONS AND COMPLIANCE 92
7.1.1 REGULATORY LANDSCAPE 92
7.1.1.1 North America 92
7.1.1.1.1 US 92
7.1.1.1.2 Canada 93
7.1.1.2 Europe 94
7.1.1.3 Asia Pacific 94
7.1.1.3.1 Japan 95
7.1.1.3.2 China 95
7.1.1.3.3 India 96
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
7.1.2.1 North America 97
7.1.2.2 Europe 97
7.1.2.3 Asia Pacific 97
7.1.2.4 Latin America 98
7.1.2.5 Middle East & Africa 98
7.2 SUSTAINABILITY INITIATIVES 98
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN
IVD RAW MATERIALS MARKET 98
7.2.1.1 Eco-friendly Initiatives 99
7.2.2 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 100
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101
8.1 DECISION-MAKING PROCESS 101
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 101
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
8.2.2 BUYING CRITERIA 102
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 104
8.5 MARKET PROFITABILITY 104
8.5.1 REVENUE POTENTIAL 105
8.5.2 COST DYNAMICS 105
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 105
9 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE 106
9.1 INTRODUCTION 107
9.2 ANTIBODIES 107
9.2.1 MONOCLONAL ANTIBODIES 110
9.2.1.1 Increasing demand for highly specific and reproducible antibody reagents in immunoassay and rapid diagnostic applications to drive segment growth 110
9.2.2 POLYCLONAL ANTIBODIES 112
9.2.2.1 Broad target recognition and strong signal generation to sustain demand for polyclonal antibodies in diagnostic assays 112
9.2.3 RECOMBINANT ANTIBODIES 114
9.2.3.1 Growing adoption of engineered antibodies to improve consistency, scalability, and performance of IVD assays 114
9.3 ANTIGENS & PROTEINS 115
9.3.1 RECOMBINANT ANTIGENS 117
9.3.1.1 Growing preference for scalable and consistent antigen production to support increasing IVD assay demand 117
9.3.2 NATIVE PROTEINS 119
9.3.2.1 Continued demand for biologically authentic proteins in sensitive assay development and clinically representative IVD applications 119
9.3.3 CALIBRATORS & STANDARDS 121
9.3.3.1 Increasing emphasis on assay standardization and traceability to drive demand for calibrators & reference materials 121
9.4 ENZYMES & SUBSTRATES 122
9.4.1 DETECTION ENZYMES 125
9.4.1.1 Increasing adoption of enzyme-based signal generation to improve sensitivity and quantitative performance of immunoassays 125
9.4.2 AMPLIFICATION ENZYMES 126
9.4.2.1 Growing adoption of molecular diagnostic testing to accelerate demand for high-performance amplification enzymes 126
9.4.3 SUBSTRATES & COENZYMES 128
9.4.3.1 Increasing need for optimized reaction components to enhance enzyme activity and diagnostic assay signal generation 128
9.5 OLIGONUCLEOTIDES & NUCLEIC ACIDS 130
9.5.1 PRIMERS & PROBES 132
9.5.1.1 Increasing adoption of PCR and multiplex molecular assays to drive demand for sequence-specific primers and probes 132
9.5.2 SYNTHETIC DNA/RNA 134
9.5.2.1 Growing use of synthetic DNA and RNA sequences to accelerate molecular assay development and validation 134
9.6 BEADS & PARTICLES 135
9.6.1 MAGNETIC BEADS 137
9.6.1.1 Growing adoption of automated magnetic-particle immunoassays to drive demand for high-performance magnetic beads 137
9.6.2 LATEX BEADS 139
9.6.2.1 Widespread use of latex particle-based agglutination and turbidimetric assays to sustain demand for latex beads 139
9.6.3 GOLD NANOPARTICLES 141
9.6.3.1 Increasing adoption of gold nanoparticle-based signal generation in rapid and visually readable diagnostic assays 141
9.7 MEMBRANES 142
9.7.1 NITROCELLULOSE MEMBRANES 144
9.7.1.1 High protein-binding capacity and controlled capillary flow to underpin nitrocellulose use across lateral flow and membrane-based immunodiagnostics 144
9.7.2 NYLON & PVDF MEMBRANES 146
9.7.2.1 Higher chemical resistance and specialized biomolecule immobilization requirements to sustain demand 146
9.7.3 GLASS FIBER PADS 148
9.7.3.1 Consistent sample and conjugate transport to strengthen role of glass fiber pads in lateral flow test construction 148
9.8 LABELS & DETECTION MATERIALS 150
9.8.1 FLUORESCENT DYES 152
9.8.1.1 Higher analytical sensitivity and instrument-based quantification to expand use of fluorescent detection in IVD 152

9.8.2 CHEMILUMINESCENT LABELS 154
9.8.2.1 Demand for ultra-sensitive immunoassays to sustain adoption of chemiluminescent labels 154
9.8.3 COLLOIDAL GOLD CONJUGATES 156
9.8.3.1 Established visual-readout capability and simplicity of lateral flow testing to sustain demand for colloidal gold conjugates 156
9.9 BUFFERS & DILUENTS 158
9.9.1 GREATER EMPHASIS ON REACTION STABILITY AND INTERFERENCE CONTROL TO SUPPORT RELIABLE IVD ASSAY PERFORMANCE 158
9.10 OTHER PRODUCTS 160
10 IVD RAW MATERIALS MARKET, BY TECHNOLOGY 163
10.1 INTRODUCTION 164
10.2 IMMUNOASSAY 164
10.2.1 INCREASING ADOPTION OF HIGH-SENSITIVITY, AUTOMATED IMMUNOASSAYS TO SUSTAIN DEMAND FOR RAW MATERIALS 164
10.3 MOLECULAR DIAGNOSTICS 166
10.3.1 EXPANSION OF PCR AND ISOTHERMAL AMPLIFICATION FORMATS TO INCREASE DEMAND FOR ENGINEERED POLYMERASES, MASTER MIXES, OLIGONUCLEOTIDES, AND NUCLEIC ACID CONTROLS 166
10.4 CLINICAL CHEMISTRY 168
10.4.1 INCREASING DEMAND FOR HIGH-QUALITY ENZYMES, PROTEINS, LIPOPROTEINS, AND REFERENCE MATERIALS TO SUPPORT AUTOMATED QUANTITATIVE TESTING 168
10.5 HEMATOLOGY 170
10.5.1 GROWING DEMAND FOR CELL-BASED REFERENCE MATERIALS AND BLOOD-DERIVED COMPONENTS TO STRENGTHEN RAW-MATERIAL REQUIREMENTS FOR HEMATOLOGY DIAGNOSTICS 170
10.6 MICROBIOLOGY & CULTURE 172
10.6.1 ADVANCES IN CULTURE-MEDIA FORMULATION AND MICROBIAL IDENTIFICATION TO STRENGTHEN DEMAND FOR SPECIALIZED MICROBIOLOGY RAW MATERIALS 172
10.7 COAGULATION TESTING 174
10.7.1 GREATER EMPHASIS ON FAST, STANDARDIZED MEASUREMENT OF CLOTTING AND FIBRINOLYSIS TO SHAPE RAW MATERIAL REQUIREMENTS IN COAGULATION DIAGNOSTICS 174
10.8 FLOW CYTOMETRY 176
10.8.1 MULTIPARAMETER CELLULAR ANALYSIS TO INCREASE DEMAND FOR HIGHLY SPECIFIC ANTIBODIES AND FLUORESCENT DETECTION MATERIALS 176
10.9 OTHER TECHNOLOGIES 178
11 IVD RAW MATERIALS MARKET, BY APPLICATION 181
11.1 INTRODUCTION 182
11.2 INFECTIOUS DISEASES 182
11.2.1 BROAD PATHOGEN COVERAGE AND FREQUENT DEMAND FOR RAPID, SENSITIVE TESTING TO DRIVE MARKET GROWTH 182

11.3 ONCOLOGY/CANCER MARKERS 184
11.3.1 MOLECULAR EXPANSION OF BIOMARKER-BASED CANCER DETECTION AND MONITORING TO INCREASE DEMAND FOR RAW MATERIALS 184
11.4 CARDIAC MARKERS 186
11.4.1 HIGH DISEASE PREVALENCE AND USE OF HIGH-SENSITIVITY BIOMARKERS TO STRENGTHEN DEMAND FOR CARDIAC-MARKER RAW MATERIALS 186
11.5 DIABETES & METABOLIC DISORDERS 188
11.5.1 EXPANDING BIOMARKER-BASED SCREENING TO SUSTAIN DEMAND FOR HBA1C, INSULIN, GLUCOSE, AND RELATED IVD RAW MATERIALS 188
11.6 AUTOIMMUNE DISEASES 190
11.6.1 GROWING RELIANCE ON AUTOANTIBODY-BASED TESTING TO SUPPORT DIAGNOSIS OF DIVERSE AUTOIMMUNE CONDITIONS AND EXPAND DEMAND FOR HIGHLY SPECIFIC IVD RAW MATERIALS 190
11.7 BLOOD SCREENING 192
11.7.1 MANDATORY SCREENING OF DONATED BLOOD AND NEED TO DETECT MULTIPLE TRANSFUSION-TRANSMISSIBLE INFECTIONS UNDERPIN DEMAND FOR DIVERSE IVD RAW MATERIALS 192
11.8 WOMEN’S HEALTH & FERTILITY 194
11.8.1 HIGH PREVALENCE OF INFERTILITY AND EXPANDING HORMONE-BASED REPRODUCTIVE TESTING TO SUSTAIN THE DEMAND 194
11.9 GENETIC & RARE DISEASE TESTING 196
11.9.1 EXPANSION OF MOLECULAR AND GENETIC TESTING TO ADDRESS A LARGE AND CLINICALLY DIVERSE POPULATION 196
11.10 OTHER APPLICATIONS 198
12 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE 201
12.1 INTRODUCTION 202
12.2 IN-HOUSE MANUFACTURING 202
12.2.1 GREATER CONTROL OVER CRITICAL REAGENTS AND ASSAY PERFORMANCE TO SUSTAIN IN-HOUSE PRODUCTION 202
12.3 THIRD-PARTY SUPPLY 204
12.3.1 OUTSOURCING SPECIALIZED CAPABILITIES TO IMPROVE FLEXIBILITY AND ACCELERATE IVD DEVELOPMENT 204
13 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN 207
13.1 INTRODUCTION 208
13.2 BIOLOGICAL/NATURAL SOURCES 208
13.2.1 ANIMAL-DERIVED 210
13.2.1.1 Established assay performance and broad availability to sustain use of animal-derived IVD raw materials 210
13.2.2 HUMAN-DERIVED 212
13.2.2.1 Clinical relevance and patient-like matrices to sustain demand for human-derived IVD raw materials 212

13.3 RECOMBINANT/SYNTHETIC SOURCES 214
13.3.1 E. COLI-EXPRESSED 217
13.3.1.1 Scalable production and strong suitability for non-glycosylated proteins to support E. coli-based recombinant IVD materials 217
13.3.2 CHO-EXPRESSED 219
13.3.2.1 Mammalian expression for structurally complex biomarkers to improve assay relevance and performance 219
13.3.3 CHEMICALLY SYNTHESIZED 221
13.3.3.1 Precisely defined composition and scalable manufacturing to expand the role of synthetic materials in IVD 221
13.4 OTHER SOURCES 223
14 IVD RAW MATERIALS MARKET, BY END USER 225
14.1 INTRODUCTION 226
14.2 IVD MANUFACTURERS 226
14.2.1 EXPANDING ASSAY PORTFOLIOS AND TIGHTER CONTROL OF CRITICAL COMPONENTS TO DRIVE RAW-MATERIAL CONSUMPTION 226
14.3 CONTRACT RESEARCH ORGANIZATIONS 228
14.3.1 INCREASING OUTSOURCING OF ASSAY DEVELOPMENT AND VALIDATION TO ACCELERATE IVD COMMERCIALIZATION 228
14.4 ACADEMIC & RESEARCH INSTITUTES 230
14.4.1 GROWING TRANSLATIONAL RESEARCH AND ASSAY DEVELOPMENT TO EXPAND CONSUMPTION OF SPECIALIZED IVD RAW MATERIALS 230
14.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 232
14.5.1 INTEGRATION OF DIAGNOSTICS INTO DRUG DEVELOPMENT TO INCREASE DEMAND FOR BIOMARKER AND ASSAY COMPONENTS 232
14.6 OTHER END USERS 234
15 IVD RAW MATERIALS MARKET, BY REGION 237
15.1 INTRODUCTION 238
15.2 NORTH AMERICA 238
15.2.1 US 246
15.2.1.1 Increasing demand for advanced diagnostics and a mature reimbursement framework to drive market 246
15.2.2 CANADA 252
15.2.2.1 Rising disease prevalence and demand for early diagnoses drive market growth 252
15.3 EUROPE 259
15.3.1 GERMANY 266
15.3.1.1 Increasing investments in life sciences and advanced diagnostics to propel demand for IVD raw materials 266
15.3.2 UK 273
15.3.2.1 Rising adoption of genomic testing and advanced diagnostics to support demand growth 273
15.3.3 FRANCE 280
15.3.3.1 High healthcare expenditure and continued investment in genomic medicine to drive market 280
15.3.4 ITALY 287
15.3.4.1 Growing geriatric population and increasing burden of chronic diseases to boost demand for IVD raw materials 287
15.3.5 SPAIN 294
15.3.5.1 Increasing adoption of genomic testing and advanced diagnostics to support the market 294
15.3.6 REST OF EUROPE 301
15.4 ASIA PACIFIC 307
15.4.1 CHINA 315
15.4.1.1 Growing focus on preventive care and localization of IVD raw materials to boost market 315
15.4.2 JAPAN 321
15.4.2.1 Increasing research investment and adoption of advanced diagnostics to support market growth 321
15.4.3 INDIA 328
15.4.3.1 Rising incidence of diabetes and cancer and increasing localization of IVD manufacturing to augment growth 328
15.4.4 REST OF ASIA PACIFIC 334
15.5 LATIN AMERICA 341
15.5.1 INCREASING HEALTHCARE INVESTMENT, DISEASE BURDEN, AND EXPANSION OF DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH 341
15.6 MIDDLE EAST & AFRICA 347
15.6.1 INCREASING HEALTHCARE INVESTMENT, PREVENTIVE SCREENING, AND DIAGNOSTIC INFRASTRUCTURE TO SUPPORT MARKET GROWTH 347
16 IVD RAW MATERIALS MARKET: VOLUME ANALYSIS 355
16.1 INTRODUCTION 355
16.2 GLOBAL: NAT BASED PCR EQUIPMENT SOLD, 2024–2031 (THOUSAND UNITS) 355
17 COMPETITIVE LANDSCAPE 356
17.1 INTRODUCTION 356
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 356
17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN IVD RAW MATERIALS MARKET 356
17.3 REVENUE ANALYSIS, 2023–2025 357
17.4 MARKET SHARE ANALYSIS, 2025 358
17.4.1 THIRD-PARTY SUPPLIERS MARKET SHARE ANALYSIS, 2025 358
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 360
17.5.1 STARS 360
17.5.2 EMERGING LEADERS 360
17.5.3 PERVASIVE PLAYERS 360
17.5.4 PARTICIPANTS 360
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 362
17.5.5.1 Company footprint 362
17.5.5.2 Region footprint 362
17.5.5.3 Product type footprint 363
17.5.5.4 End-user footprint 364
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 364
17.6.1 PROGRESSIVE COMPANIES 364
17.6.2 RESPONSIVE COMPANIES 364
17.6.3 DYNAMIC COMPANIES 365
17.6.4 STARTING BLOCKS 365
17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 366
17.6.5.1 Detailed list of key startups/SMEs 366
17.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 366
17.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 367
17.7 COMPANY VALUATION & FINANCIAL METRICS 367
17.7.1 FINANCIAL METRICS 367
17.7.2 COMPANY VALUATION 368
17.8 BRAND/PRODUCT COMPARISON 369
17.9 COMPETITIVE SCENARIO 370
17.9.1 PRODUCT LAUNCHES & APPROVALS 370
17.9.2 DEALS 370
18 COMPANY PROFILES 372
18.1 KEY PLAYERS 372
18.1.1 MERCK KGAA 372
18.1.1.1 Business overview 372
18.1.1.2 Products offered 373
18.1.1.3 Recent developments 380
18.1.1.3.1 Product launches & approvals 380
18.1.1.3.2 Deals 380
18.1.1.4 MnM view 380
18.1.1.4.1 Key strengths 380
18.1.1.4.2 Strategic choices 380
18.1.1.4.3 Weaknesses and competitive threats 381
18.1.2 THERMO FISHER SCIENTIFIC 382
18.1.2.1 Business overview 382
18.1.2.2 Products offered 383
18.1.2.3 Recent developments 389
18.1.2.3.1 Product enhancements 389
18.1.2.3.2 Deals 389
18.1.2.4 MnM view 389
18.1.2.4.1 Key strengths 389
18.1.2.4.2 Strategic choices 390
18.1.2.4.3 Weaknesses & competitive threats 390
18.1.3 BIO-TECHNE CORPORATION 391
18.1.3.1 Business overview 391
18.1.3.2 Products & services offered 392
18.1.3.3 Recent developments 399
18.1.3.3.1 Product launches & approvals 399
18.1.3.3.2 Deals 399
18.1.3.4 MnM view 399
18.1.3.4.1 Key strengths 399
18.1.3.4.2 Strategic choices 399
18.1.3.4.3 Weaknesses & competitive threats 400
18.1.4 FAPON BIOTECH 401
18.1.4.1 Business overview 401
18.1.4.2 Products & services offered 402
18.1.4.3 Recent developments 407
18.1.4.3.1 Product launches & approvals 407
18.1.4.4 MnM view 407
18.1.4.4.1 Key strengths 407
18.1.4.4.2 Strategic choices 407
18.1.4.4.3 Weaknesses & competitive threats 407
18.1.5 MERIDIAN BIOSCIENCE 408
18.1.5.1 Business overview 408
18.1.5.2 Products offered 409
18.1.5.3 Recent developments 415
18.1.5.3.1 Product launches 415
18.1.5.3.2 Deals 415
18.1.5.4 MnM view 415
18.1.5.4.1 Key strengths 415
18.1.5.4.2 Strategic choices 415
18.1.5.4.3 Weaknesses & competitive threats 415
18.1.6 MEDIX BIOCHEMICA 416
18.1.6.1 Business overview 416
18.1.6.2 Products & services offered 417
18.1.6.3 Recent developments 422
18.1.6.3.1 Deals 422
18.1.6.3.2 Expansions 423
18.1.7 ROCHE CUSTOMBIOTECH 424
18.1.7.1 Business overview 424
18.1.7.2 Products & services offered 425
18.1.8 DANAHER CORPORATION 431
18.1.8.1 Business overview 431
18.1.8.2 Products & services offered 432
18.1.8.3 Recent developments 440
18.1.8.3.1 Deals 440
18.1.9 SARTORIUS AG 441
18.1.9.1 Business overview 441
18.1.9.2 Products offered 442
18.1.10 HYTEST LTD. 445
18.1.10.1 Business overview 445
18.1.10.2 Products offered 445
18.1.11 TOYOBO CO., LTD. 453
18.1.11.1 Business overview 453
18.1.11.2 Products offered 454
18.1.12 LGC BIOSEARCH TECHNOLOGIES 460
18.1.12.1 Business overview 460
18.1.12.2 Products offered 461
18.2 OTHER PLAYERS 466
18.2.1 BBI SOLUTIONS 466
18.2.2 SURMODICS IVD 467
18.2.3 AHLSTROM OYJ 468
18.2.4 BANGS LABORATORIES 469
18.2.5 SCRIPPS LABORATORIES, INC. 470
18.2.6 MIKROGEN GMBH 471
18.2.7 ADVANCED MICRODEVICES PVT. LTD. 472
18.2.8 SEKISUI DIAGNOSTICS 473
18.2.9 RANDOX LABORATORIES LTD. 474
18.2.10 HIMEDIA LABORATORIES 475
18.2.11 SINO BIOLOGICAL 476
18.2.12 BIOSYNTH 477
18.2.13 NEW ENGLAND BIOLABS, INC. 478
19 RESEARCH METHODOLOGY 479
19.1 RESEARCH DATA 479
19.2 SECONDARY DATA 480
19.2.1 LIST OF SECONDARY SOURCES 480
19.2.2 PRIMARY DATA 481
19.2.2.1 Key data from primary sources 482
19.2.2.2 Breakdown of primary interviews 484
19.3 MARKET SIZE ESTIMATION 484
19.3.1 TOTAL MARKET SIZE: IVD RAW MATERIALS MARKET 485
19.3.2 BOTTOM-UP APPROACH 485
19.3.2.1 Approach 2: Study of annual reports and investor presentations 485
19.3.2.2 Approach 3: Primary interviews 486
19.3.2.3 Growth forecast 486
19.3.3 TOP-DOWN APPROACH 487
19.4 DATA TRIANGULATION 487
19.5 RESEARCH ASSUMPTIONS 488
19.5.1 STUDY-RELATED ASSUMPTIONS 488
19.6 STUDY ASSUMPTIONS 489
19.6.1 GROWTH RATE ASSUMPTIONS 490
19.7 RESEARCH LIMITATIONS 490
19.8 RISK ASSESSMENT 490
20 APPENDIX 491
20.1 DISCUSSION GUIDE 491
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 496
20.3 CUSTOMIZATION OPTIONS 498
20.4 RELATED REPORTS 498
20.5 AUTHOR DETAILS 499

List of Tables

TABLE 1 RECENT INDICATORS SUPPORTING PERSONALIZED MEDICINE
AND COMPANION DIAGNOSTICS 57
TABLE 2 RECENT INDUSTRY DEVELOPMENTS SUPPORTING RECOMBINANT
BIOMOLECULE ADOPTION 57
TABLE 3 PORTER’S FIVE FORCES ANALYSIS: IMPACT ANALYSIS 69
TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 70
TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS 71
TABLE 6 EUROPE: MACROECONOMIC INDICATORS 71
TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS 72
TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS 72
TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 72
TABLE 10 IVD RAW MATERIALS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 75
TABLE 11 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, BY REGION, 2024–2026 (USD) 76
TABLE 12 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, KEY PLAYER,
2024–2026 (USD) 77
TABLE 13 IMPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78
TABLE 14 EXPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78
TABLE 15 IVD RAW MATERIALS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 79
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 81
TABLE 17 IVD RAW MATERIALS MARKET—KEY TECHNOLOGIES 84
TABLE 18 KEY PATENTS IN IVD RAW MATERIALS, 2023–2026 88
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN IVD RAW MATERIALS MARKET 91
TABLE 20 US: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 93
TABLE 21 CANADA: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 93
TABLE 22 JAPAN: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 95
TABLE 23 CHINA: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 96
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 97
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 97
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 97
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 98
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 102
TABLE 30 KEY BUYING CRITERIA, BY END USER 102
TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
TABLE 32 IVD RAW MATERIALS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 104
TABLE 33 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 107
TABLE 34 ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 108
TABLE 35 ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 109
TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 39 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 111
TABLE 40 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 111
TABLE 41 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 111
TABLE 42 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 112
TABLE 43 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 112
TABLE 44 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 113
TABLE 45 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 113
TABLE 46 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 113
TABLE 47 RECOMBINANT ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 114
TABLE 48 NORTH AMERICA: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 114
TABLE 49 EUROPE: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 115
TABLE 50 ASIA PACIFIC: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 115
TABLE 51 ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 116
TABLE 52 ANTIGENS & PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 116
TABLE 53 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 116
TABLE 54 EUROPE: ANTIGENS & PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 117
TABLE 55 ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 117
TABLE 56 RECOMBINANT ANTIGENS MARKET, BY REGION, 2024–2031 (USD MILLION) 118
TABLE 57 NORTH AMERICA: RECOMBINANT ANTIGENS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 118
TABLE 58 EUROPE: RECOMBINANT ANTIGENS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 118
TABLE 59 ASIA PACIFIC: RECOMBINANT ANTIGENS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 119
TABLE 60 NATIVE PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 61 NORTH AMERICA: NATIVE PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 120
TABLE 62 EUROPE: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 63 ASIA PACIFIC: NATIVE PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 120
TABLE 64 CALIBRATORS & STANDARDS MARKET, BY REGION, 2024–2031 (USD MILLION) 121
TABLE 65 NORTH AMERICA: CALIBRATORS & STANDARDS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 121
TABLE 66 EUROPE: CALIBRATORS & STANDARDS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 122
TABLE 67 ASIA PACIFIC: CALIBRATORS & STANDARDS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 122
TABLE 68 ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 123
TABLE 69 ENZYMES & SUBSTRATES MARKET, BY REGION, 2024–2031 (USD MILLION) 123
TABLE 70 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 71 EUROPE: ENZYMES & SUBSTRATES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 72 ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 73 DETECTION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 74 NORTH AMERICA: DETECTION ENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 125
TABLE 75 EUROPE: DETECTION ENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 76 ASIA PACIFIC: DETECTION ENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 77 AMPLIFICATION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 78 NORTH AMERICA: AMPLIFICATION ENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 127
TABLE 79 EUROPE: AMPLIFICATION ENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 128
TABLE 80 ASIA PACIFIC: AMPLIFICATION ENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 128
TABLE 81 SUBSTRATES & COENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 129
TABLE 82 NORTH AMERICA: SUBSTRATES & COENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 83 EUROPE: SUBSTRATES & COENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 84 ASIA PACIFIC: SUBSTRATES & COENZYMES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 130
TABLE 85 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 130
TABLE 86 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY REGION,
2024–2031 (USD MILLION) 131
TABLE 87 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 88 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 131
TABLE 89 ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 90 PRIMERS & PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 91 NORTH AMERICA: PRIMERS & PROBES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 92 EUROPE: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 93 ASIA PACIFIC: PRIMERS & PROBES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 94 SYNTHETIC DNA/RNA MARKET, BY REGION, 2024–2031 (USD MILLION) 134
TABLE 95 NORTH AMERICA: SYNTHETIC DNA/RNA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 96 EUROPE: SYNTHETIC DNA/RNA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 97 ASIA PACIFIC: SYNTHETIC DNA/RNA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 98 BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 136
TABLE 99 BEADS & PARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 100 NORTH AMERICA: BEADS & PARTICLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 101 EUROPE: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 102 ASIA PACIFIC: BEADS & PARTICLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 103 MAGNETIC BEADS MARKET, BY REGION, 2024–2031 (USD MILLION) 138
TABLE 104 NORTH AMERICA: MAGNETIC BEADS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 138
TABLE 105 EUROPE: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 106 ASIA PACIFIC: MAGNETIC BEADS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 107 LATEX BEADS MARKET, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 108 NORTH AMERICA: LATEX BEADS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 109 EUROPE: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 110 ASIA PACIFIC: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 111 GOLD NANOPARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 112 NORTH AMERICA: GOLD NANOPARTICLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 113 EUROPE: GOLD NANOPARTICLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 114 ASIA PACIFIC: GOLD NANOPARTICLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 115 MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 143
TABLE 116 MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 117 NORTH AMERICA: MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 143
TABLE 118 EUROPE: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 119 ASIA PACIFIC: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 120 NITROCELLULOSE MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 121 NORTH AMERICA: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 122 EUROPE: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 123 ASIA PACIFIC: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 124 NYLON & PVDF MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 147
TABLE 125 NORTH AMERICA: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 147
TABLE 126 EUROPE: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 127 ASIA PACIFIC: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 128 GLASS FIBER PADS MARKET, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 129 NORTH AMERICA: GLASS FIBER PADS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 130 EUROPE: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 131 ASIA PACIFIC: GLASS FIBER PADS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 132 LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 151
TABLE 133 LABELS & DETECTION MATERIALS MARKET, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 134 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 135 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 136 ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 137 FLUORESCENT DYES MARKET, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 138 NORTH AMERICA: FLUORESCENT DYES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 139 EUROPE: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 140 ASIA PACIFIC: FLUORESCENT DYES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 141 CHEMILUMINESCENT LABELS MARKET, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 142 NORTH AMERICA: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 143 EUROPE: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 144 ASIA PACIFIC: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 145 COLLOIDAL GOLD CONJUGATES MARKET, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 146 NORTH AMERICA: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 147 EUROPE: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 148 ASIA PACIFIC: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 149 BUFFERS & DILUENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 159
TABLE 150 NORTH AMERICA: BUFFERS & DILUENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 151 EUROPE: BUFFERS & DILUENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 152 ASIA PACIFIC: BUFFERS & DILUENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 153 IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY REGION,
2024–2031 (USD MILLION) 161
TABLE 154 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 155 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 156 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 157 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 164
TABLE 158 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 165
TABLE 159 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 160 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 161 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 162 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 167
TABLE 163 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 164 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 165 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 166 CLINICAL CHEMISTRY MARKET, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 167 NORTH AMERICA: CLINICAL CHEMISTRY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 168 EUROPE: CLINICAL CHEMISTRY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 169 ASIA PACIFIC: CLINICAL CHEMISTRY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 170 HEMATOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 171
TABLE 171 NORTH AMERICA: HEMATOLOGY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 172 EUROPE: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 173 ASIA PACIFIC: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 174 MICROBIOLOGY & CULTURE MARKET, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 175 NORTH AMERICA: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 173
TABLE 176 EUROPE: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 174
TABLE 177 ASIA PACIFIC: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 174
TABLE 178 COAGULATION TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 175
TABLE 179 NORTH AMERICA: COAGULATION TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 175
TABLE 180 EUROPE: COAGULATION TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 181 ASIA PACIFIC: COAGULATION TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 182 FLOW CYTOMETRY MARKET, BY REGION, 2024–2031 (USD MILLION) 177
TABLE 183 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 177
TABLE 184 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 185 ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 178
TABLE 186 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 179
TABLE 187 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 188 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 189 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 190 IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 182
TABLE 191 IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2024–2031 (USD MILLION) 183
TABLE 192 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 193 EUROPE: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 194 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 195 IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS,
BY REGION, 2024–2031 (USD MILLION) 185
TABLE 196 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 197 EUROPE: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 198 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 199 IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY REGION,
2024–2031 (USD MILLION) 187
TABLE 200 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 201 EUROPE: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS,
BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 202 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS,
BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 203 IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 189
TABLE 204 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 205 EUROPE: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 206 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 207 IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY REGION,
2024–2031 (USD MILLION) 191
TABLE 208 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 209 EUROPE: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 210 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 211 IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY REGION,
2024–2031 (USD MILLION) 193
TABLE 212 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 213 EUROPE: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 214 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 215 IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 216 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 217 EUROPE: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY,
BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 218 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 219 IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING,
BY REGION, 2024–2031 (USD MILLION) 197
TABLE 220 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 221 EUROPE: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 222 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 223 IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 199
TABLE 224 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 225 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 226 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 227 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 202
TABLE 228 IN-HOUSE MANUFACTURING MARKET, BY REGION, 2024–2031 (USD MILLION) 203
TABLE 229 NORTH AMERICA: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 230 EUROPE: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 231 ASIA PACIFIC: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 204
TABLE 232 THIRD-PARTY SUPPLY MARKET, BY REGION, 2024–2031 (USD MILLION) 205
TABLE 233 NORTH AMERICA: THIRD-PARTY SUPPLY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 205
TABLE 234 EUROPE: THIRD-PARTY SUPPLY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 205
TABLE 235 ASIA PACIFIC: THIRD-PARTY SUPPLY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 206
TABLE 236 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 208
TABLE 237 BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 238 BIOLOGICAL/NATURAL SOURCES MARKET, BY REGION,
2024–2031 (USD MILLION) 209
TABLE 239 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 240 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 210
TABLE 241 ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 210
TABLE 242 ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY REGION,
2024–2031 (USD MILLION) 211
TABLE 243 NORTH AMERICA: ANIMAL-DERIVED IVD RAW MATERIALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 244 EUROPE: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 212
TABLE 245 ASIA PACIFIC: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 246 HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 247 NORTH AMERICA: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 248 EUROPE: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 214
TABLE 249 ASIA PACIFIC: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 250 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 215
TABLE 251 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 252 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 253 EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 216
TABLE 254 ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 255 E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION,
2024–2031 (USD MILLION) 217
TABLE 256 NORTH AMERICA: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 257 EUROPE: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 258 ASIA PACIFIC: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 259 CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION,
2024–2031 (USD MILLION) 219
TABLE 260 NORTH AMERICA: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 261 EUROPE: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 262 ASIA PACIFIC: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 263 CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY REGION,
2024–2031 (USD MILLION) 221
TABLE 264 NORTH AMERICA: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 265 EUROPE: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 266 ASIA PACIFIC: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 267 OTHER IVD RAW MATERIAL SOURCES MARKET, BY REGION,
2024–2031 (USD MILLION) 223
TABLE 268 NORTH AMERICA: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 269 EUROPE: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 224
TABLE 270 ASIA PACIFIC: IVD RAW MATERIAL OTHER SOURCES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 224
TABLE 271 IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 226
TABLE 272 IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY REGION,
2024–2031 (USD MILLION) 227
TABLE 273 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS,
BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 274 EUROPE: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 275 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 276 IVD RAW MATERIALS MARKET FOR CROS, BY REGION, 2024–2031 (USD MILLION) 229
TABLE 277 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 278 EUROPE: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 279 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 280 IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2024–2031 (USD MILLION) 231
TABLE 281 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 282 EUROPE: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 283 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 284 IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 285 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 286 EUROPE: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 287 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 288 IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 235
TABLE 289 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 290 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 291 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 292 IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 238
TABLE 293 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 240
TABLE 294 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 241
TABLE 295 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 296 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY TYPE,
2024–2031 (USD MILLION) 242
TABLE 297 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY TYPE,
2024–2031 (USD MILLION) 242
TABLE 298 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 299 NORTH AMERICA: BEADS & PARTICLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 243
TABLE 300 NORTH AMERICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 301 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 243
TABLE 302 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 244
TABLE 303 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 244
TABLE 304 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 245
TABLE 305 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 245
TABLE 306 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 245
TABLE 307 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 246
TABLE 308 US: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 247
TABLE 309 US: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 310 US: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 311 US: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 312 US: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 248
TABLE 313 US: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 314 US: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 315 US: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 249
TABLE 316 US: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 250
TABLE 317 US: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250
TABLE 318 US: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 251
TABLE 319 US: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 251
TABLE 320 US: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 321 US: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 322 US: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 252
TABLE 323 CANADA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 253
TABLE 324 CANADA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 325 CANADA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 326 CANADA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 327 CANADA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 255
TABLE 328 CANADA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 329 CANADA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 330 CANADA: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 331 CANADA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 256
TABLE 332 CANADA: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 257
TABLE 333 CANADA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 257
TABLE 334 CANADA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 258
TABLE 335 CANADA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 258
TABLE 336 CANADA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 258
TABLE 337 CANADA: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 259
TABLE 338 EUROPE: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 339 EUROPE: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 261
TABLE 340 EUROPE: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 341 EUROPE: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 342 EUROPE: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 343 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 262
TABLE 344 EUROPE: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 345 EUROPE: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 346 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 263
TABLE 347 EUROPE: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 264
TABLE 348 EUROPE: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 264
TABLE 349 EUROPE: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 265
TABLE 350 EUROPE: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 265
TABLE 351 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 352 EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 266
TABLE 353 EUROPE: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 266
TABLE 354 GERMANY: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 268
TABLE 355 GERMANY: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 356 GERMANY: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 357 GERMANY: ENZYMES & SUBSTRATES MARKET, BY TYPE,
2024–2031 (USD MILLION) 269
TABLE 358 GERMANY: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 269
TABLE 359 GERMANY: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 360 GERMANY: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 361 GERMANY: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 362 GERMANY: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 271
TABLE 363 GERMANY: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 271
TABLE 364 GERMANY: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 272
TABLE 365 GERMANY: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 272
TABLE 366 GERMANY: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 272
TABLE 367 GERMANY: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 273
TABLE 368 GERMANY: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 273
TABLE 369 UK: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 275
TABLE 370 UK: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 371 UK: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 372 UK: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 373 UK: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 276
TABLE 374 UK: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 375 UK: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 376 UK: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 277
TABLE 377 UK: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 278
TABLE 378 UK: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 278
TABLE 379 UK: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 279
TABLE 380 UK: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 279
TABLE 381 UK: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 382 UK: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 383 UK: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 280
TABLE 384 FRANCE: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 282
TABLE 385 FRANCE: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 386 FRANCE: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 387 FRANCE: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 388 FRANCE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 283
TABLE 389 FRANCE: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 390 FRANCE: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 391 FRANCE: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 284
TABLE 392 FRANCE: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 285
TABLE 393 FRANCE: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 285
TABLE 394 FRANCE: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 286
TABLE 395 FRANCE: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 286
TABLE 396 FRANCE: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 286
TABLE 397 FRANCE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 287
TABLE 398 FRANCE: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 287
TABLE 399 ITALY: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 289
TABLE 400 ITALY: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 401 ITALY: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 402 ITALY: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 403 ITALY: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 290
TABLE 404 ITALY: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 405 ITALY: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 406 ITALY: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 407 ITALY: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 292
TABLE 408 ITALY: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 292
TABLE 409 ITALY: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 293
TABLE 410 ITALY: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 293
TABLE 411 ITALY: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 293
TABLE 412 ITALY: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 294
TABLE 413 ITALY: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 294
TABLE 414 SPAIN: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 295
TABLE 415 SPAIN: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 416 SPAIN: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 417 SPAIN: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 418 SPAIN: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 419 SPAIN: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 420 SPAIN: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 421 SPAIN: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 298
TABLE 422 SPAIN: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 298
TABLE 423 SPAIN: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 299
TABLE 424 SPAIN: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 299
TABLE 425 SPAIN: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 300
TABLE 426 SPAIN: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 300
TABLE 427 SPAIN: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 300
TABLE 428 SPAIN: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 301
TABLE 429 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 302
TABLE 430 REST OF EUROPE: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 431 REST OF EUROPE: ANTIGENS & PROTEINS MARKET, BY TYPE,
2024–2031 (USD MILLION) 303
TABLE 432 REST OF EUROPE: ENZYMES & SUBSTRATES MARKET, BY TYPE,
2024–2031 (USD MILLION) 303
TABLE 433 REST OF EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 434 REST OF EUROPE: BEADS & PARTICLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 435 REST OF EUROPE: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 436 REST OF EUROPE: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 437 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 305
TABLE 438 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 305
TABLE 439 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 306
TABLE 440 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 306
TABLE 441 REST OF EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 306
TABLE 442 REST OF EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 307
TABLE 443 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 307
TABLE 444 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 309
TABLE 445 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 309
TABLE 446 ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 447 ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY TYPE,
2024–2031 (USD MILLION) 310
TABLE 448 ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY TYPE,
2024–2031 (USD MILLION) 310
TABLE 449 ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 311
TABLE 450 ASIA PACIFIC: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 451 ASIA PACIFIC: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 452 ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 312
TABLE 453 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 312
TABLE 454 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 313
TABLE 455 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 313
TABLE 456 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 314
TABLE 457 ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 314
TABLE 458 ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 314
TABLE 459 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 315
TABLE 460 CHINA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 316
TABLE 461 CHINA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 462 CHINA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 463 CHINA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 464 CHINA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 317
TABLE 465 CHINA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 466 CHINA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 467 CHINA: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 318
TABLE 468 CHINA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 319
TABLE 469 CHINA: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 319
TABLE 470 CHINA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 320
TABLE 471 CHINA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 320
TABLE 472 CHINA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 320
TABLE 473 CHINA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 321
TABLE 474 CHINA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 321
TABLE 475 JAPAN: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 322
TABLE 476 JAPAN: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 477 JAPAN: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 478 JAPAN: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 479 JAPAN: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 324
TABLE 480 JAPAN: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 481 JAPAN: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 482 JAPAN: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 325
TABLE 483 JAPAN: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 325
TABLE 484 JAPAN: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 326
TABLE 485 JAPAN: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 326
TABLE 486 JAPAN: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 327
TABLE 487 JAPAN: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 327
TABLE 488 JAPAN: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 327
TABLE 489 JAPAN: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 328
TABLE 490 INDIA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 329
TABLE 491 INDIA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 492 INDIA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 493 INDIA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 494 INDIA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 330
TABLE 495 INDIA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 496 INDIA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 497 INDIA: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 331
TABLE 498 INDIA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 332
TABLE 499 INDIA: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 332
TABLE 500 INDIA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 333
TABLE 501 INDIA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 333
TABLE 502 INDIA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 333
TABLE 503 INDIA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 334
TABLE 504 INDIA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 334
TABLE 505 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 335
TABLE 506 REST OF ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 507 REST OF ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY TYPE,
2024–2031 (USD MILLION) 336
TABLE 508 REST OF ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY TYPE,
2024–2031 (USD MILLION) 336
TABLE 509 REST OF ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 510 REST OF ASIA PACIFIC: BEADS & PARTICLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 337
TABLE 511 REST OF ASIA PACIFIC: MEMBRANES MARKET, BY TYPE,
2024–2031 (USD MILLION) 337
TABLE 512 REST OF ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 513 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 338
TABLE 514 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 339
TABLE 515 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 339
TABLE 516 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 340
TABLE 517 REST OF ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 340
TABLE 518 REST OF ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 519 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 341
TABLE 520 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 342
TABLE 521 LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 522 LATIN AMERICA: ANTIGENS & PROTEINS MARKET, BY TYPE,
2024–2031 (USD MILLION) 343
TABLE 523 LATIN AMERICA: ENZYMES & SUBSTRATES MARKET, BY TYPE,
2024–2031 (USD MILLION) 343
TABLE 524 LATIN AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE,
2024–2031 (USD MILLION) 343
TABLE 525 LATIN AMERICA: BEADS & PARTICLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 344
TABLE 526 LATIN AMERICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 527 LATIN AMERICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE,
2024–2031 (USD MILLION) 344
TABLE 528 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 345
TABLE 529 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 345
TABLE 530 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE,
2024–2031 (USD MILLION) 346
TABLE 531 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN,
2024–2031 (USD MILLION) 346
TABLE 532 LATIN AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 346
TABLE 533 LATIN AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE,
2024–2031 (USD MILLION) 347
TABLE 534 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 347
TABLE 535 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 349
TABLE 536 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY TYPE,
2024–2031 (USD MILLION) 349
TABLE 537 MIDDLE EAST & AFRICA: ANTIGENS & PROTEINS MARKET, BY TYPE,
2024–2031 (USD MILLION) 350
TABLE 538 MIDDLE EAST & AFRICA: ENZYMES & SUBSTRATES MARKET, BY TYPE,
2024–2031 (USD MILLION) 350
TABLE 539 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 540 MIDDLE EAST & AFRICA: BEADS & PARTICLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 351
TABLE 541 MIDDLE EAST & AFRICA: MEMBRANES MARKET, BY TYPE,
2024–2031 (USD MILLION) 351
TABLE 542 MIDDLE EAST & AFRICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 543 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 352
TABLE 544 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 352
TABLE 545 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 353
TABLE 546 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 353
TABLE 547 MIDDLE EAST & AFRICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 353
TABLE 548 MIDDLE EAST & AFRICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 354
TABLE 549 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY END USER,
2024–2031 (USD MILLION) 354
TABLE 550 GLOBAL: NAT BASED PCR EQUIPMENT SOLD, 2024–2031 (THOUSAND UNITS) 355
TABLE 551 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN IVD RAW MATERIALS MARKET, JANUARY 2023−JULY 2026 356
TABLE 552 IVD RAW MATERIALS MARKET: DEGREE OF COMPETITION 359
TABLE 553 IVD RAW MATERIALS MARKET: REGION FOOTPRINT 362
TABLE 554 IVD RAW MATERIALS MARKET: PRODUCT TYPE FOOTPRINT 363
TABLE 555 IVD RAW MATERIALS MARKET: END-USER FOOTPRINT 364
TABLE 556 IVD RAW MATERIALS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 366
TABLE 557 IVD RAW MATERIALS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 366
TABLE 558 IVD RAW MATERIALS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 367
TABLE 559 IVD RAW MATERIALS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JULY 2026 370
TABLE 560 IVD RAW MATERIALS MARKET: DEALS, JANUARY 2023– JULY 2026 370
TABLE 561 MERCK KGAA: COMPANY OVERVIEW 372
TABLE 562 MERCK KGAA: PRODUCTS OFFERED 373
TABLE 563 MERCK KGAA: PRODUCT LAUNCHES & APPROVALS 380
TABLE 564 MERCK KGAA: DEALS 380
TABLE 565 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 382
TABLE 566 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 383
TABLE 567 THERMO FISHER SCIENTIFIC INC.: PRODUCT ENHANCEMENTS 389
TABLE 568 THERMO FISHER SCIENTIFIC INC.: DEALS 389
TABLE 569 BIO-TECHNE CORPORATION: COMPANY OVERVIEW 391
TABLE 570 BIO-TECHNE CORPORATION: PRODUCTS & SERVICES OFFERED 392
TABLE 571 BIO-TECHNE CORPORATION: PRODUCT LAUNCHES & APPROVALS 399
TABLE 572 BIO-TECHNE CORPORATION: DEALS 399
TABLE 573 FAPON BIOTECH: COMPANY OVERVIEW 401
TABLE 574 FAPON BIOTECH: PRODUCTS & SERVICES OFFERED 402
TABLE 575 FAPON BIOTECH: PRODUCT LAUNCHES & APPROVALS 407
TABLE 576 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW 408
TABLE 577 MERIDIAN BIOSCIENCE: PRODUCTS OFFERED 409
TABLE 578 MERIDIAN BIOSCIENCE: PRODUCT LAUNCHES 415
TABLE 579 MERIDIAN BIOSCIENCE: DEALS 415
TABLE 580 MEDIX BIOCHEMICA: COMPANY OVERVIEW 416
TABLE 581 MEDIX BIOCHEMICA: PRODUCTS & SERVICES OFFERED 417
TABLE 582 MEDIX BIOCHEMICA: DEALS 422
TABLE 583 MEDIX BIOCHEMICA: EXPANSIONS 423
TABLE 584 F. HOFFMANN-LA ROCHE: COMPANY OVERVIEW 424
TABLE 585 ROCHE CUSTOMBIOTECH: PRODUCTS & SERVICES OFFERED 425
TABLE 586 DANAHER CORPORATION: COMPANY OVERVIEW 431
TABLE 587 DANAHER CORPORATION: PRODUCTS OFFERED 432
TABLE 588 DANAHER CORPORATION: DEALS 440
TABLE 589 SARTORIUS AG: COMPANY OVERVIEW 441
TABLE 590 SARTORIUS AG: PRODUCTS OFFERED 442
TABLE 591 HYTEST LTD.: COMPANY OVERVIEW 445
TABLE 592 HYTEST LTD.: PRODUCTS OFFERED 445
TABLE 593 TOYOBO CO., LTD.: COMPANY OVERVIEW 453
TABLE 594 TOYOBO CO., LTD.: PRODUCTS OFFERED 454
TABLE 595 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 460
TABLE 596 LGC BIOSEARCH TECHNOLOGIES: PRODUCTS OFFERED 461
TABLE 597 BBI SOLUTIONS: COMPANY OVERVIEW 466
TABLE 598 SURMODICS IVD: COMPANY OVERVIEW 467
TABLE 599 AHLSTROM OYJ: COMPANY OVERVIEW 468
TABLE 600 BANGS LABORATORIES: COMPANY OVERVIEW 469
TABLE 601 SCRIPPS LABORATORIES, INC.: COMPANY OVERVIEW 470
TABLE 602 MIKROGEN GMBH: COMPANY OVERVIEW 471
TABLE 603 ADVANCED MICRODEVICES PVT. LTD.: COMPANY OVERVIEW 472
TABLE 604 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 473
TABLE 605 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 474
TABLE 606 HIMEDIA LABORATORIES: COMPANY OVERVIEW 475
TABLE 607 SINO BIOLOGICAL: COMPANY OVERVIEW 476
TABLE 608 BIOSYNTH: COMPANY OVERVIEW 477
TABLE 609 NEW ENGLAND BIOLABS, INC.: COMPANY OVERVIEW 478

List of Figures

FIGURE 1 IVD RAW MATERIALS MARKET SEGMENTATION 42
FIGURE 2 REGIONAL SCOPE 43
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 45
FIGURE 4 GLOBAL IVD RAW MATERIALS MARKET, 2024–2031 45
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IVD
RAW MATERIALS MARKET, 2023–2026 46
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IVD RAW MATERIALS MARKET 47
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN
IVD RAW MATERIALS MARKET, 2025 48
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49
FIGURE 9 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 50
FIGURE 10 ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51
FIGURE 11 IMMUNOASSAY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51
FIGURE 12 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52
FIGURE 13 IN-HOUSE MANUFACTURING SEGMENT TO LEAD MARKET
DURING FORECAST PERIOD 52
FIGURE 14 BIOLOGICAL/NATURAL SOURCES TO LEAD MARKET DURING FORECAST PERIOD 53
FIGURE 15 IVD MANUFACTURERS SEGMENT TO COMMAND LARGEST
SHARE DURING FORECAST PERIOD 53
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 54
FIGURE 17 IVD RAW MATERIALS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 55
FIGURE 18 IVD RAW MATERIALS MARKET: PORTER’S FIVE FORCES ANALYSIS 68
FIGURE 19 IVD RAW MATERIALS MARKET: SUPPLY CHAIN ANALYSIS 73
FIGURE 20 IVD RAW MATERIALS MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 21 IVD RAW MATERIALS MARKET: ECOSYSTEM ANALYSIS 75
FIGURE 22 IVD RAW MATERIALS MARKET: TRENDS AND DISRUPTIONS
IMPACTING CUSTOMER BUSINESS 80
FIGURE 23 DEALS & FUNDING ACTIVITIES IN IVD RAW MATERIALS MARKET 80
FIGURE 24 PATENT ANALYSIS FOR IVD RAW MATERIALS, JANUARY 2016–DECEMBER 2025 87
FIGURE 25 MARKET POTENTIAL OF AI IN IVD RAW MATERIALS MARKET 90
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 101
FIGURE 27 KEY BUYING CRITERIA, BY END USER 102
FIGURE 28 NORTH AMERICA: IVD RAW MATERIALS MARKET SNAPSHOT 240
FIGURE 29 ASIA PACIFIC: IVD RAW MATERIALS MARKET SNAPSHOT 308
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN IVD RAW MATERIALS MARKET,
2023–2025 (USD MILLION) 358
FIGURE 31 IVD RAW MATERIALS MARKET SHARE ANALYSIS, 2025 (GLOBAL) 358
FIGURE 32 IVD RAW MATERIALS MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2025 361
FIGURE 33 IVD RAW MATERIALS MARKET: COMPANY FOOTPRINT 362
FIGURE 34 IVD RAW MATERIALS MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 365
FIGURE 35 EV/EBITDA OF KEY VENDORS 367
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 368
FIGURE 37 IVD RAW MATERIALS MARKET: BRAND/PRODUCT COMPARISON FOR RECOMBINANT HUMAN IL-6 PROTEIN 369
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2025) 373
FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2025) 383
FIGURE 40 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2025) 392
FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025) 425
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 432
FIGURE 43 SARTORIUS AG: COMPANY SNAPSHOT (2025) 442
FIGURE 44 TOYOBO CO., LTD.: COMPANY SNAPSHOT (2025) 454
FIGURE 45 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2025) 461
FIGURE 46 RESEARCH DESIGN 479
FIGURE 47 KEY DATA FROM SECONDARY SOURCES 481
FIGURE 48 LIST OF PRIMARY SOURCES 482
FIGURE 49 KEY INDUSTRY INSIGHTS 483
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 484
FIGURE 51 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS 485
FIGURE 52 CAGR PROJECTIONS 486
FIGURE 53 TOP-DOWN APPROACH 487
FIGURE 54 DATA TRIANGULATION 488
FIGURE 55 PARAMETRIC ASSUMPTIONS 489

---

---